Bioartificial liver based on human iPSCs-induced hepatocyte-like cells and multilayer porous bioreactor

Abstract

The invention discloses a bioartificial liver based on human iPSCs-induced hepatocytes and a multilayer porous bioreactor. Plasma separation column, first pressure monitor and heater, cell reactor/plasma component exchange double cycle part including plasma input peristaltic pump connected to plasma outlet in sequence and semi-permeable membrane exchange column in special incubator at 37°C, plasma exchange Peristaltic pump, red blood cell pool, membrane lung, multi-layer porous bioreactor, second and third pressure monitors, the outlet of the third pressure monitor and the outlet of blood cells are connected to the inlet of the first pressure monitor together, and then connected in sequence Heater and blood output tube. The present invention can maintain the temperature and oxygen supply required by the cells through the cooperation of the two circulation parts, improve the liquid exchange efficiency and biocompatibility at the same time, meet the clinical needs, and reduce the risk of heterogeneous virus infection and immune response risk.

Description

technical field [0001] The invention relates to the technical field of bioartificial liver, in particular to a bioartificial liver based on iPSCs-induced hepatic cells and a multilayer porous bioreactor. Background technique [0002] Bioartificial liver (BAL) is a new type of liver support system that uses human or animal-derived liver cells to temporarily or partially replace the failed liver function in the body, and can assist in the treatment of liver failure or related liver diseases. BAL not only has the function of liver detoxification, but also can achieve liver synthesis, metabolism, secretion and other functions through the hepatocytes in the reactor, and is expected to fundamentally replace the function of the liver. In recent years, BAL research has made great progress, and it has shown a certain role in liver support. Human liver cancer cell lines such as C3A cells have been used in the bioartificial liver system (ELAD) in the United States, but they have low m...

AI Technical Summary

Problems solved by technology

Human liver cancer cell lines such as C3A cells have been used in the bioartificial liver system (ELAD) in the United States, but they have low metabolic defects, and experiments have proved that the source cell of C3A, HepG2, has no therapeutic effect on ALF mice; Pig-derived primary liver cells have also been used in AMC-BAL and HepatAssist systems abroad; these cell sources have been criticized for their immunogenicity (pig-resistant IgG was found in vivo after clinical application), and have animal Risk of source virus infection

Images